ACRV vs MTB · $65.1M cap vs P/E 12, rev $860.0M
Acrivon Therapeutics, Inc. Common Stock (ACRV) versus M&T Bank Corporation (MTB) — a side-by-side from cached financials, not a winner call.
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
M&T Bank Corporation (MTB) is a banks - regional company listed on US.
ACRV does not have a complete income-statement cache yet.
Latest reported MTB revenue for 2026-06-30 was $860.0M. Net income was $1.48B. MTB currently screens at market cap $30.99B and trailing P/E 11.9.
ACRV currently screens at market cap $65.1M. MTB currently screens at market cap $30.99B and trailing P/E 11.9.
Not investment advice. Open the ACRV and MTB stock pages for the full models.
Not investment advice.